Marked hypofrontality in clozapine-responsive patients

Pharmacopsychiatry

Volumn 40, Issue 4, 2007, Pages 157-162

  Molina, V ^a,b   Sanz, J ^b   Sarramea, F ^c   Palomo, T ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUORODEOXYGLUCOSE F 18;

ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG MECHANISM; HUMAN; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; THALAMUS; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CAUDATE NUCLEUS; CLOZAPINE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; RADIOPHARMACEUTICALS; SCHIZOPHRENIA; THALAMUS;

EID: 34548707897     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984399     Document Type: Article

References (43)

1. 2O technique, Part 2: Choosing a significance threshold. Am J Psychiatry 1996; 153: 6
2. Andreasen NC, Rezai K, Alliger R, Swayze VWd, Flaum M, Kirchner P, Cohen G, O'Leary DS. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992; 49: 943-958
3. Barbas H. Architecture and cortical connections of the prefrontal cortex in the rhesus monkey. Adv Neurol 1992; 57: 91-115
4. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Wolf AP, Fowler JS, Volkow ND, Smith G, Wolkin A et al. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry 1994; 151: 681-686
5. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Katz M, Lohr J, Wu J, Lottenberg S, Jerabek PA et al. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 1992; 49: 935-942
6. Cohen RM, Nordahl TE, Semple WE, Andreason P, Litman RE, Pickar D. The brain metabolic patterns of clozapine- and fluphenazine- treated patients with schizophrenia during a continuous performance task. Arch Gen Psychiatry 1997; 54: 481-486
7. Desco M, Gispert J, Reig S, Sanz J, Pascau J, Sarramea F, Benito C, Santos A, Palomo T, Molina V. Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry Res: Neuroimaging 2003; 122: 125-135
8. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science 1986; 1: 54-77
9. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Human Brain function. Academic Press: New York, 1997
10. Fuster J (editor), The prefrontal lobe. Philadelphia: Lippincott-Raven, 1997
11. Fuster J. Chemical Neurotransmission. In: Fuster J (editor), The prefrontal lobe. Philadelphia: Lippincott-Raven, 1997; 61
12. Fuster JM. Synopsis of function and dysfunction of the frontal lobe. Acta Psychiatr Scand Suppl 1999; 395: 51-57
13. Gispert JD, Pascau J, Reig S, Martinez-Lazaro R, Molina V, Garcia-Barreno P, Desco M. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage 2003; 19: 601-612
14. Grobin AC, Deutch AY. Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat. J Pharmacol Exp Ther 1998; 285: 350-357
15. Gross A, Joutsiniemi SL, Rimon R, Appelberg B. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry 2004; 37: 119-122
16. Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ, Alpert NM. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1998; 1: 318-323
17. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Donnals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996; 153: 41-49
18. Huntley GW, Vickers JC, Morrison JH. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci 1994; 17: 536-543
19. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Tamminga CA. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry 2003; 53: 601-608
20. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998; 42: 211-221
21. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160: 179-186
22. Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 1989; 238: 332-339
23. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5: 267-271
24. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol Psychiatry 2001; 49: 704-715
25. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990; 54: 1755-1760
26. Molina Rodriguez V, Montz Andree R, Perez Castejon MJ, Capdevila Garcia E, Carreras Delgado JL, Rubia Vila FJ. SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am J Psychiatry 1996; 153: 1343-1346
27. Molina V, Gispert JD, Reig S, Pascau J, Palomo T, Martínez R, Desco M. Olanzapine-induced cerebral metabolic changes. Relation to symptom changes in schizophrenia. Int Clin Psychopharmacol 2005a; 20: 13-18
28. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, Desco M, Palomo T. Cerebral metabolic changes induced by clozapine in schizophrenia. Psychopharmacology 2005; 178: 17-26
29. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, Palomo T, Desco M. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophrenia Res 2003; 60: 1-7
30. Molina V, Sanz J, Reig S, Martínez R, Sarramea F, Luque R, Benito C, Gispert JD, Pascau J, Desco M. Hypofrontality in males with first-episode psychosis. Br J Psychiatry 2005; 186: 203-208
31. Molina V, Reig S, Sarramea F, Sanz J, Artaloytia FJ, Luque R, Aragüés M, Pascau J, Benito C, Palomo T, Desco M. Anatomical and functional brain variables associated to clozapine response in treatment-resistant schizophrenia. Psychiatry Res:Neuroimaging 2003; 124: 153-161
32. Molina V, Sarramea F, Sanz J, Benito C, Palomo T. Prefrontal atrophy in first episodes of schzophrenia associated with limbic hyperactivity. J Psychiatric Res 2005; 39: 117-127
33. Poline JB, Worsley KJ, Evans AC, Friston KJ. Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage 1997; 5: 83-96
34. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney Jr WE, Fallon JH, Kennedy JL. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003; 8: 109-113
35. 99mTc-HMPAO study. Psychiatry Res 1997; 76: 51-61
36. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Thieme Medical Stuttgart, New York, 1988
37. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004; 161: 1620-1625
38. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 2002; 77: 501-505
39. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002; 12: 1063-1070
40. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572-575
41. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 2004; 27: 683-690
42. Yamamoto BK, Pehek EA, Meltzer HY. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 1994; 55 (Suppl B): 8-14
43. Zink M, Schmitt A, May B, Muller B, Braus DF, Henn FA. Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression. Pharmacopsychiatry 2004; 37: 171-174